Recent Updates — MCTA

The Nasdaq Stock Market notified Charming Medical Limited that it will be delisted from the exchange due to a determination by Listing Qualifications Staff under Rule IM-5101-4. This action follows an October 29, 2026 letter and stems from a U.S. Securities and Exchange Commission order issued on November 11, 2025, which suspended trading in the company's securities due to potential manipulation via social media recommendations designed to artificially inflate price and volume. Unless Charming Medical requests an appeal by November 5, 2026, trading will be suspended at the opening of business on November 9, 2026, after which Nasdaq will file a Form 25-NSE to remove the securities from listing. The company states that the delisting does not affect its ongoing operations or financial condition and may seek trading in the over-the-counter market. Charming Medical Limited is a Hong Kong-based provider of Traditional Chinese Medicine-inspired therapies and products.

Charming Medical Limited is holding an extraordinary general meeting on October 23, 2026, to vote on proposals to cancel its authorized but unissued Class B shares and remove the company's dual-class share structure. The filing seeks shareholder approval to reduce the maximum number of authorized shares from 75,000,000 to 60,000,000 single-class ordinary shares with a par value of US$0.0001 each. As of the September 25, 2026 record date, 15,178,000 Class A shares were issued and outstanding, while all previously issued Class B shares had been surrendered and cancelled. The company operates in the medical device industry.